Search research articles
Contact Us
Filters
Showing results (61-70 of 90) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
The Oncologist
|
February 14, 2019
Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location
Irit Ben-Aharon, Tal Goshen-Lago, Michal Sternschuss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
The Oncologist
|
February 22, 2023
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
Josep Tabernero, Eric Van Cutsem, Elena Garralda, et al.
Journal for Immunotherapy of Cancer
|
August 14, 2021
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
Sarina A Piha-Paul, Ravit Geva, Tira J Tan, et al.
Biomed Research International
|
July 11, 2015
Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
Ron Epelbaum, Einat Shacham-Shmueli, Baruch Klein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 23, 2016
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients
Baruch Brenner, Ravit Geva, Megan Rothney, et al.
Journal of Clinical & Translational Endocrinology
|
September 4, 2023
Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity
Esther Osher, Ravit Geva, Ido Wolf, et al.
Familial Cancer
|
August 31, 2013
Lynch Syndrome in high risk Ashkenazi Jews in Israel
Yael Goldberg, Inbal Kedar, Revital Kariiv, et al.
The Lancet. Oncology
|
May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 90) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
The Oncologist
|
February 14, 2019
Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location
Irit Ben-Aharon, Tal Goshen-Lago, Michal Sternschuss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
The Oncologist
|
February 22, 2023
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
Josep Tabernero, Eric Van Cutsem, Elena Garralda, et al.
Journal for Immunotherapy of Cancer
|
August 14, 2021
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
Sarina A Piha-Paul, Ravit Geva, Tira J Tan, et al.
Biomed Research International
|
July 11, 2015
Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
Ron Epelbaum, Einat Shacham-Shmueli, Baruch Klein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 23, 2016
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients
Baruch Brenner, Ravit Geva, Megan Rothney, et al.
Journal of Clinical & Translational Endocrinology
|
September 4, 2023
Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity
Esther Osher, Ravit Geva, Ido Wolf, et al.
Familial Cancer
|
August 31, 2013
Lynch Syndrome in high risk Ashkenazi Jews in Israel
Yael Goldberg, Inbal Kedar, Revital Kariiv, et al.
The Lancet. Oncology
|
May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Page
of 9